Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study

Inflammatory Bowel Diseases

Volumn 17, Issue 4, 2011, Pages 937-946

  Andersen, Vibeke ^a   Nimmo, Elaine ^b   Krarup, Henrik B ^c   Drummond, Hazel ^b   Christensen, Jane ^d   Ho, Gwo Tzer ^b   Østergaard, Mette ^a   Ernst, Anja ^c   Lees, Charlie ^b   Jacobsen, Bent A ^c   Satsangi, Jack ^b   Vogel, Ulla ^e,f,g  

^a VIBORG HOSPITAL   (Denmark)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^f ROSKILDE UNIVERSITY   (Denmark)

^g NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

Author keywords

Crohn's disease; Single nucleotide polymorphisms; Smoking status; Ulcerative colitis

Indexed keywords

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROHN DISEASE; CYCLOOXYGENASE 2 GENE; DENMARK; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; ULCERATIVE COLITIS; UNITED KINGDOM;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOOXYGENASE 2; DENMARK; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SCOTLAND; YOUNG ADULT;

EID: 79952460646     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21440     Document Type: Article

References (54)

1. Andersen V, Ernst A, Christensen J, et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet.2010;11:82.
2. Lees CW, Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol. 2009;3:513-534.
3. Ernst A, Andersen V, Ostergaard M, et al. Genetic variants of glutathione S-transferases mu, theta, and pi display no susceptibility to inflammatory bowel disease in the Danish population. Scand J Gastroenterol. 2010 [Epub ahead of print].
4. Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol. 2003;37:358-367. (Pubitemid 37296163)
5. Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis: rationale, methodology, and present status of the field. Inflamm Bowel Dis. 2004;10:300-311. (Pubitemid 38618262)
6. Economou M, Pappas G. New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709-720. (Pubitemid 351742998)
7. Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol. 2006;18:601-606.
8. Ernst A, Jacobsen B, Ostergaard M, et al. Mutations in CARD15 and smoking confer susceptibility to Crohn's disease in the Danish population. Scand J Gastroenterol. 2007;42:1445-1451. (Pubitemid 350125541)
9. Hugot JP, Zaccaria I, Cavanaugh J, et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol. 2007;102:1259-1267. (Pubitemid 46802011)
10. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640. (Pubitemid 46722636)
11. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521. (Pubitemid 46348505)
12. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. (Pubitemid 47123518)
13. Fukata M, Chen A, Klepper A, et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology. 2006;131:862-877. (Pubitemid 44316821)
14. Tsatsanis C, Androulidaki A, Venihaki M, et al. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006;38:1654-1661. (Pubitemid 43947653)
15. Scher JU, Pillinger MH. The anti-inflammatory effects of prostaglandins. J Investig Med. 2009;57:703-708.
16. Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Sci World J. 2006;6:577-588. (Pubitemid 43793980)
17. Sheibanie AF, Yen JH, Khayrullina T, et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 - >IL-17 axis. J Immunol. 2007;178:8138-8147. (Pubitemid 46898086)
18. Karmeli F, Cohen P, Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol. 2000;12:223-231. (Pubitemid 30166690)
19. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation- associated colonic injury in rat through inhibition of cyclooxygenase- 2. J Clin Invest. 1996;98:2076-2085. (Pubitemid 26376296)
20. Okayama M, Hayashi S, Aoi Y, et al. Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci. 2007;52:2095-2103. (Pubitemid 47246503)
21. Kapoor M, Kojima F, Yang L, et al. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids. 2007;76:103-112. (Pubitemid 46217229)
22. Rajakariar R, Yaqoob MM, Gilroy DW. COX-2 in inflammation and resolution. Mol Interv. 2006;6:199-207. (Pubitemid 44455202)
23. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112:387-397. (Pubitemid 27078825)
24. Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol. 1997;92:1170-1173. (Pubitemid 27304815)
25. Singer II, Kawka DW, Schloemann S, et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 1998;115:297-306. (Pubitemid 28363422)
26. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology. 2005;129:565-576. (Pubitemid 41096644)
27. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res. 2007;617:138-146.
28. Andersen V, Ostergaard M, Christensen J, et al. Polymorphisms in the xenobiotic transporter multidrug resistance 1 (MDR1) gene and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:407.
29. Sanak M, Szczeklik W, Szczeklik A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol. 2005;116:221-223. (Pubitemid 40909772)
30. Cox DG, Crusius JB, Peeters PH, et al. Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J Gastroenterol. 2005;11:6003-6008. (Pubitemid 41749216)
31. Ostergaard M, Ernst A, Labouriau R, et al. Cyclooxygenase-2, multi-drug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand J Gastroenterol. 2009;44:65-73.
32. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation. 2005;112:941-945. (Pubitemid 41170260)
33. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res. 2005;65:664-670.
34. Badawi AF, Habib SL, Mohammed MA, et al. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest. 2002;20:651-656. (Pubitemid 37210035)
35. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462-1471.
36. Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol. 2007;102:577-588. (Pubitemid 46328158)
37. Aldhous MC, Drummond HE, Anderson N, et al. Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol. 2007;102:589-597. (Pubitemid 46328159)
38. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. (Pubitemid 34851835)
39. Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25:229-235. (Pubitemid 38239806)
40. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6:356-365.
41. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res. 2007;617:138-146.
42. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008;639:89-100.
43. Hakansson A, Bergman O, Chrapkowska C, et al. Cyclooxygenase-2 polymorphisms in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:367-369. (Pubitemid 46642031)
44. Hedelin M, Chang ET, Wiklund F, et al. Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer. 2007;120:398-405. (Pubitemid 44956853)
45. HapMap: Rs689466:http://www.ncbi.nlm.nih.gov/projects/SNP/snp-ref.cgi?rs= 689466. 2010.
46. Dossus L, Kaaks R, Canzian F, et al. PTGS2 and IL6 Genetic Variation and Risk of Breast and Prostate Cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010;31:455-461.
47. Siezen CL, van Leeuwen AI, Kram NR, et al. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis. 2005;26:449-457. (Pubitemid 40246567)
48. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, et al. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer. 2006;119:297-303.
49. Ulrich CM, Whitton J, Yu JH, et al. PTGS2 (COX-2)-765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev. 2005;14:616-619.
50. Gao J, Ke Q, Ma HX, et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A. 2007;70:908-915. (Pubitemid 46699715)
51. Tan W, Wu J, Zhang X, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2007;28:1197-1201. (Pubitemid 47064309)
52. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2004;CD004722.
53. Arnott ID, Nimmo ER, Drummond HE, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?Genes Immun.2004;5:417-425.
54. Genetic Power Calculator; http://pngu.mgh.harvard.edu/≈purcell/gpc/ cc2.html. 2009.